

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Amgen Ltd (Blinatumomab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer 52 Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Kararwa Leukaemia Trust Leukaemia Cancer Society Leukaemia Care Macmillan Cancer Support Maggie's Centres Marie Curie South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care WMUK <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> Association of Anaesthetists Association of Cancer Physicians Association of Surgeons of Great Britain and Ireland British Blood Transfusion Society British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Hospital Information Services – Jehovah's Witnesses Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Blood and Transplant NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> Accord UK Ltd (cytarabine, doxorubicin, etoposide, methotrexate) ADVANZ Pharma (methotrexate) Almus Pharmaceuticals Ltd (methotrexate) Amgen Ltd (blinatumomab) Aspen Pharma Trading Ltd (mercaptopurine)

Provisional stakeholder list for the evaluation of Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

Issue date: April 2024

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Psychosocial Oncology Society • British Society for Haematology • British Society of Blood and Marrow Transplantation and Cellular Therapy • British Society of Interventional Radiology • British Transplantation Society • Cancer Research UK • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<ul style="list-style-type: none"> • Baxter Healthcare Ltd (doxorubicin, cyclophosphamide) • Cipla EU Ltd (methotrexate) • Consilient Health Ltd (etoposide) • Esteve Pharmaceuticals Ltd (methotrexate) • Fontus Health Ltd (mercaptopurine) • Fresenius Kabi Ltd (etoposide) • Hospira UK Ltd (cytarabine, methotrexate, vincristine) • Jazz Pharmaceuticals UK (cytarabine, daunorubicin) • medac GmbH (asparaginase, doxorubicin, etoposide, methotrexate) • Medihealth (Northern) Ltd (mercaptopurine, methotrexate) • Morningside Healthcare Ltd (methotrexate) • Neon Healthcare Ltd (etoposide) • Nordic Pharma Ltd (methotrexate) • Nova Laboratories Ltd (mercaptopurine) • Orion Pharma (UK) Ltd (methotrexate) • Pfizer Ltd (cytarabine, doxorubicin, methotrexate, vincristine) • Rosemont Pharmaceuticals Ltd (methotrexate) • Sandoz Ltd (cyclophosphamide, methotrexate) • Seacross Pharmaceuticals Ltd (doxorubicin) • Sigma Pharmaceuticals Plc (methotrexate) • Teva Ltd (methotrexate, vincristine) • Therakind Ltd (methotrexate) • Zentiva Pharma UK Ltd (daunorubicin) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Haematological Group • Cochrane UK • Genomics England • Institute of Cancer Research • Leukaemia Busters • Leukaemia UK • MRC Clinical Trials Unit

Provisional stakeholder list for the evaluation of Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

Issue date: April 2024

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.